Envoy Medical (COCH) Net Income towards Common Stockholders (2021 - 2026)

Envoy Medical has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$5.7 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$5.7 million, up 8.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.1 million (down 5.84% YoY), and the FY2025 annual result was -$28.7 million, down 2.46% from the prior year.
• Net Income towards Common Stockholders came in at -$5.7 million for Q1 2026 at Envoy Medical, up from -$7.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $10.6 million in Q2 2022 to a low of -$13.3 million in Q1 2023.
• The 5-year median for Net Income towards Common Stockholders is -$6.9 million (2025), against an average of -$5.5 million.
• Across the five-year window, Net Income towards Common Stockholders soared 14213.81% in 2022 and tumbled 631.76% in 2023, its largest moves.
• Envoy Medical's Net Income towards Common Stockholders stood at -$11.5 million in 2022, then surged by 45.6% to -$6.2 million in 2023, then decreased by 23.09% to -$7.7 million in 2024, then slipped by 0.66% to -$7.7 million in 2025, then rose by 26.32% to -$5.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$5.7 million (Q1 2026), -$7.7 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.